This Phase 2 clinical trial is positioned to evaluate a novel combination therapy for AML patients who have previously failed or are intolerant to the Venetoclax plus Azacitidine regimen. The target patient population is significant, given the high unmet medical need in relapsed/refractory AML. If successful, this combination could provide a competitive edge in a market dominated by limited treatment options for this patient demographic. The trial's location in China may also offer strategic advantages in terms of regulatory pathways and market entry, particularly in the Asia-Pacific region, which is experiencing rapid growth in oncology therapeutics. Companies should monitor the trial's progress closely for potential partnership or acquisition opportunities, especially if the results demonstrate a favorable safety and efficacy profile.